Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer

DOI10.2307/2531628zbMATH Open0715.62242OpenAlexW2076108528WikidataQ48901121 ScholiaQ48901121MaRDI QIDQ70258FDOQ70258

John O'Quigley, John O'Quigley, Lloyd Fisher, Lloyd Fisher, M. Pepe

Publication date: March 1990

Published in: Biometrics (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.2307/2531628

Recommendations

• Continual reassessment and related dose-finding designs
• Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials
• A new design of the continual reassessment method
• Continual reassessment method with multiple toxicity constraints
• A class of designs for phase I cancer clinical trials combining Bayesian and likelihood approaches

zbMATH Keywords

cancerdose escalationdose-findingphase I clinical trialstoxicity curve

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cited In (only showing first 100 items - show all)

• Convergence properties of sequential Bayesian \(D\)-optimal designs
• Monitoring the Rates of Composite Events with Censored Data in Phase II Clinical Trials
• A conversation with Nancy Flournoy
• Bayesian models and decision algorithms for complex early phase clinical trials
• Analysis of ``learn-as-you-go (LAGO) studies
• A note on the robustness of the continual reassessment method
• Approximate dynamic programming and its applications to the design of Phase I cancer trials
• A bayesian predictive approach to sequential search for an optimal dose: Parametric and nonparametric models
• The treatment versus experimentation dilemma in dose finding studies
• A new design of the continual reassessment method
• Random-effects meta-analysis of phase I dose-finding studies using stochastic process priors
• On the Use of Nonparametric Curves in Phase I Trials with Low Toxicity Tolerance
• Sequential Monte Carlo for Bayesian sequentially designed experiments for discrete data
• Patient-specific dose finding in phase I clinical trials
• Curve-Free and Model-Based Continual Reassessment Method Designs
• A note on continual reassessment method
• Adaptive isotonic estimation of the minimum effective and peak doses in the presence of covariates
• Dose‐finding methods for Phase I clinical trials using pharmacokinetics in small populations
• Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
• Adaptive designs for dose-finding based on efficacy-toxicity response
• Optimal sequential designs in phase I studies
• Designs foe phase i cancer clinical trials with differentiation of graded toxicity
• Operating characteristics of the standard phase I clinical trial design.
• Optimal designs for dose-escalation trials and individual allocations in cohorts
• A Curve‐Free Method for Phase I Clinical Trials
• A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents
• Sequential Methods in Multi-Arm Clinical Trials
• Implementation of a Bayesian Design in a Dose‐Escalation Study of an Experimental Agent in Healthy Volunteers
• Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics
• Dose-Finding Designs for HIV Studies
• Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
• Optimal Bayesian-feasible dose escalation for cancer phase I trials
• A Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment Method
• Unifying CRM and EWOC designs for phase I cancer clinical trials
• Continual reassessment method for partial ordering
• Continual reassessment method with multiple toxicity constraints
• Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control
• A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
• Incorporating Individual and Collective Ethics into Phase I Cancer Trial Designs
• Ethical considerations concerning treatment allocation in drug development trials
• Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
• Cumulative cohort design for dose-finding
• Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
• Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials
• Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
• Theoretical study of the continual reassessment method
• Adaptive Bayesian compound designs for dose finding studies
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• SEQUENTIAL METHODS IN CLINICAL TRIALS*
• Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information
• Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach
• Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials
• Bayesian phase I/II adaptively randomized oncology trials with combined drugs
• Efficiency of bridging between related dose finding studies
• Using a one-parameter model to sequentially estimate the root of a regression function.
• A Phase I Bayesian Adaptive Design to Simultaneously Optimize Dose and Schedule Assignments Both Between and Within Patients
• The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
• A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes
• Target toxicity design for phase I dose-finding
• On the consistency of the continual reassessment method with multiple toxicity constraints
• Designs for Single- or Multiple-Agent Phase I Trials
• Performance Measures in Dose‐Finding Experiments
• Dynamic calibration of pharmacokinetic parameters in dose-finding studies
• escalation
• An application of reinforced urn processes to determining maximum tolerated dose
• Adaptive designs for selecting drug combinations based on efficacy-toxicity response
• Continual reassessment and related dose-finding designs
• Stochastic approximation and modern model-based designs for dose-finding clinical trials
• Design efficiency in dose finding studies
• trialr
• Optimal adaptive generalized Pólya urn design for multi-arm clinical trials
• Impact of different model structure and prior distribution in continual reassessment method
• Flexible link continual reassessment methods for trivariate binary outcome phase I/II trials
• A new look at evaluating MTD designs in cancer research
• On optimal designs for clinical trials: an updated review
• A Semiparametric Sequential Algorithm for Estimation of Dose–Response Curve
• Statistical frameworks for oncology dose-finding designs with late-onset toxicities: a review
• A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies
• BIPSE: a biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint
• TITE-BOIN12: a Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy
• DROID: dose-ranging approach to optimizing dose in oncology drug development
• The adaptive accelerated biased coin design for phase I clinical trials
• A Bayesian design for phase I cancer therapeutic vaccine trials
• PA‐CRM: A continuous reassessment method for pediatric phase I oncology trials with concurrent adult trials
• A class of designs for Phase I cancer clinical trials combining Bayesian and likelihood approaches
• Designs for Phase I Clinical Trials with Multiple Courses of Subjects at Different Doses
• Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies
• Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial
• Dose-Finding Based on Feasibility and Toxicity in T-cell Infusion Trials
• A continual reassessment method without undue risk of toxicity
• Title not available (Why is that?)
• Multivariate Markov models for the conditional probability of toxicity in phase II trials
• Sequential method of estimating the LD₅₀ using a modified up-and-down rule
• The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
• A modified Huber loss function for continual reassessment methods in clinical trials
• DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses
• A simulation-free approach to assessing the performance of the continual reassessment method
• Fractional accumulative calibration-free odds (f-aCFO) design for delayed toxicity in phase I clinical trials
• REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors
• A novel approach for propensity score matching and stratification for multiple treatments: application to an electronic health record-derived study

This page was built for publication: Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q70258)